Sector Gamma AS Purchases New Position in TG Therapeutics, Inc. $TGTX

Key Points

• Sector Gamma AS has acquired 55,000 shares of TG Therapeutics, Inc. for approximately $2.17 million, signaling increased institutional interest in the biopharmaceutical company.
• In Q1, several hedge funds boosted their holdings in TG Therapeutics, with Russell Investments Group Ltd. increasing its position by 338.6%, now owning 152,214 shares.
• TG Therapeutics reported $0.17 EPS for the latest quarter, missing expectations, and a revenue of $141.15 million, showing a 92.1% year-over-year increase.

Sector Gamma AS acquired a new position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 55,000 shares of the biopharmaceutical company's stock, valued at approximately $2,169,000.

Several other institutional investors have also recently bought and sold shares of the company. Nuveen LLC bought a new position in shares of TG Therapeutics in the 1st quarter valued at about $29,442,000. Raymond James Financial Inc. acquired a new stake in shares of TG Therapeutics during the fourth quarter worth $14,508,000. Penn Capital Management Company LLC acquired a new position in TG Therapeutics in the 4th quarter valued at $10,577,000. Invesco Ltd. boosted its position in shares of TG Therapeutics by 30.2% during the 1st quarter. Invesco Ltd. now owns 1,210,842 shares of the biopharmaceutical company's stock worth $47,744,000 after acquiring an additional 281,099 shares in the last quarter. Finally, First Trust Advisors LP lifted its position in shares of TG Therapeutics by 871.7% during the 4th quarter. First Trust Advisors LP now owns 275,496 shares of the biopharmaceutical company's stock worth $8,292,000 after buying an additional 247,145 shares during the last quarter. Institutional investors own 58.58% of the company's stock.

Insider Buying and Selling

In other news, Director Yann Echelard sold 10,000 shares of TG Therapeutics stock in a transaction that occurred on Friday, June 13th. The stock was sold at an average price of $36.94, for a total value of $369,400.00. Following the sale, the director directly owned 228,816 shares in the company, valued at approximately $8,452,463.04. This trade represents a 4.19% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 10.64% of the stock is owned by company insiders.

TG Therapeutics Stock Performance

Shares of TG Therapeutics stock traded up $0.19 during trading hours on Tuesday, hitting $27.92. 1,643,613 shares of the company's stock traded hands, compared to its average volume of 2,503,634. The company has a fifty day simple moving average of $34.83 and a 200-day simple moving average of $35.84. The company has a debt-to-equity ratio of 0.89, a current ratio of 3.86 and a quick ratio of 2.96. The stock has a market capitalization of $4.43 billion, a price-to-earnings ratio of 75.46 and a beta of 1.95. TG Therapeutics, Inc. has a 12-month low of $21.11 and a 12-month high of $46.48.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last posted its quarterly earnings data on Monday, August 4th. The biopharmaceutical company reported $0.17 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.32 by ($0.15). The company had revenue of $141.15 million for the quarter, compared to analysts' expectations of $147.76 million. TG Therapeutics had a return on equity of 26.05% and a net margin of 13.31%.The business's quarterly revenue was up 92.1% on a year-over-year basis. During the same quarter last year, the business posted $0.04 EPS. TG Therapeutics has set its FY 2025 guidance at EPS. Equities research analysts anticipate that TG Therapeutics, Inc. will post 0.08 EPS for the current fiscal year.

Analyst Ratings Changes

Separately, The Goldman Sachs Group upgraded shares of TG Therapeutics to a "hold" rating and set a $37.00 target price on the stock in a research report on Thursday, July 10th. Three research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $46.25.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.